anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A derivative of penicillin or cephalosporin antibiotics of formulaI[R1 is formula II or III; Y is formula IV (R 2 is hydroxyl), formula V (R3 is formula IV where R4 is H, 1-4C alkyl, salt, -OR4]. EXAMPLE:4-Nitrophenyl-7-(triophene-2-acetamide)thiocephalosporanate. USE:Antibacterial: it comes into blood with no adverse effect on enterally useful bacteria to show antibacterial activity at this stage. Further, its acute toxicity is low. PREPARATION:For example, the compound of formula VIII (R1 is formula II where formula III is excluded; Y' is formula IX) or its salt is added to a solvent such as acetone and further, a activating agent such as a carbodiimide is added thereto. A compound of X-R5 (X is -NH2, Br, Cl; R5 is formula X) is added to the reaction system and their reaction is conducted at -30-50 deg.C for 0.5- 48hr.
PURPOSE: A mask pack is provided to ensure antibacterial effect and skin moisturization. CONSTITUTION: A mask pack comprises a mask sheet(2), pack(3) and essence(4). The mask pack(1) is produced by joining silk and cotton yarn containing silver nano particle which is obtained from cocoon of silk worm. The cocoon is grown by feeding with nano. The mask sheet is formed with non-woven fabric by joining silk and cotton yarn. The sheet is sealed and contained in the pack. The essence is filled in the pack and absorbed into the mask.
Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive regular insulin (U100, 40 IU) at visit 3 during second intervention period.
Several mental disorders can be classified as psychotic disorders, such as schizophrenia and manic depression. Psychosis is a defining feature of psychotic disorders, and is characterized by delusions and hallucinations that result in extreme impairment of a person's ability to think clearly. First-episode psychosis refers to the first time someone experiences psychotic symptoms or a psychotic episode. The symptoms can be disturbing and unfamiliar to those who have not previously experienced them. The person experiencing first-episode psychosis may not understand what is happening, and may become confused and distressed. Psychosis is treatable, however, and most people recover. Standard treatment for psychosis entails a combination of behavioral therapy and drug therapy. GRIP is a comprehensive psychosocial intervention for people recovering from an initial episode of non-affective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. This study will determine the effectiveness of GRIP in enhancing the clinical benefit of routine treatment for individuals recovering from their first episodes of psychosis.

Participants in this study will be randomly assigned to receive either treatment as usual (TAU) or TAU plus GRIP. Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management; substance use; persistent symptoms; and functional recovery. Assessments of social functioning, psychotic symptoms, attitudes toward treatment, substance use, and hospital readmission rate will be assessed at baseline, mid-treatment, post-treatment, and at the follow-up visit 3 months post-treatment.
Embodiments of the present invention provide a method and system for dynamically controlling an appliance based on information received from a wearable device, to regulate the user's health. A wearable device is identified and configured to monitor at least one physiological aspect of the user. A controllable appliance with at least one sensor and at least one controllable setting is also identified. Health information of the user is received and utilized in generating, a user profile which comprises parameters related to the health of the user. Data from the wearable device and data from the controllable appliance is analyzed and it is determined whether the data matches the parameters related to the health of the user. If the data does not match the parameters related to the health of the user, then at least one controllable setting of the at least one controllable appliance is adjusted.
Sepsis is a medical emergency resulting from a dysregulated response to an infection, causing preventable deaths and a high burden of morbidity. Protocolized and accurate interventions in sepsis are time-critical. Therefore, earlier recognition of cases allows for preventive interventions, early treatment, and improved outcomes. Clinical diagnosis of sepsis by clinical scores cannot be considered an early diagnosis, given that underlying molecular pathophysiological mechanisms have been activated in the preceding hour or days. There is a lack of a widely available tool enhancing preclinical diagnosis of sepsis. Sophisticated technologies for sepsis prediction have several limitations, including high costs. Novel technologies for fast molecular and microbiological diagnosis are focusing on bedside point-of-care combined testing to reach most settings where sepsis represents a challenge.
BACKGROUND: Approximately 40% of treated head and neck cancer (HNC) patients develop recurrence. The risk of recurrence declines with time from treatment. Current guidelines recommend clinical follow-up every two months for the first two years after treatment, with reducing intensity over the next three years. However, evidence for the effectiveness of these regimes in detecting recurrence is lacking, with calls for more flexible, patient-centred follow-up strategies.
METHODS: PETNECK2 is a UK-based multi-centre programme examining a new paradigm of follow-up, using positron emission tomography-computed tomography (PET-CT)-guided, symptom-based, patient-initiated surveillance. This paradigm is being tested in a unblinded, non-inferiority, phase III, randomised controlled trial (RCT). Patients with HNC, one year after completing curative intent treatment, with no clinical symptoms or signs of loco-regional or distant metastasis will be randomised using a 1:1 allocation ratio to either regular scheduled follow-up, or to PET-CT guided, patient-initiated follow-up. Patients at a low risk of recurrence (negative PET-CT) will receive a face-to-face education session along with an Information and Support (I&S) resource package to monitor symptoms and be in control of initiating an urgent appointment when required. The primary outcome of the RCT is overall survival. The RCT also has an in-built pilot, a nested QuinteT Recruitment Intervention (QRI), and a nested mixed-methods study on patient experience and fear of cancer recurrence (FCR). An initial, single-arm feasibility study has been completed which determined the acceptability of the patient-initiated surveillance intervention, the completion rates of baseline questionnaires, and optimised the I&S resource prior to implementation in the RCT.
DISCUSSION: We hypothesise that combining an additional 12-month post-treatment PET-CT scan and I&S resource will both identify patients with asymptomatic recurrence and identify those at low risk of future recurrence who will be empowered to monitor their symptoms and seek early clinical follow-up when recurrence is suspected. This change to a patient-centred model of care may have effects on both quality of life and fear of cancer recurrence.
TRIAL REGISTRATION: ISRCTN: 13,709,798; 15-Oct-2021.
Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
NEW MATERIAL:A compound shown by the formula I (R1 is H or OH; R2 is H, OH or amino). EXAMPLE:7-Hydroxyguanine riboside. USE:An antitumor agent. PREPARATION:A 7-hydroxyguanine shown by the formula II or its salt and a saccharide-1-phosphoric acid (e.g., 2-deoxyribose-1-phosphoric acid, etc.) shown by the formula III as substrates are treated with nucleoside phosphorylase or a bacterium [e.g., bacterium belonging to the genus Achromobacter, etc.] having the activity to give a compound shown by the formula I. 7- Hydoxyguanine used as the substrate can be prepared from a culture solution of Streptomyces sp. A-347 (FERM BP-541).
Group A participants will wear the necklace with essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace without essential oil for last 4 weeks (the sixth to ninth weeks).
Hydrophilic polymers obtained by cast polymerising a hydrophilic ester of an unsaturated carboxylic acid are converted to particulate form, e.g. powder, beads or comminuted extrusions, and formed into cigarette filter elements or tips. The polymers are preferably derived from hydroxypropyl or 2-hydroxyethyl acrylate or methacrylate, and ethylene glycol dimethacrylate. The element or tip is preferably impregnated with a humectant, e.g. glycerine, propylene glycol, polypropylene glycol or ethylene glycol. Other optional additives include tobacco flavouring and menthol.
Semi-structured interviews of stakeholder groups will be conducted by MUSC researchers who are well-trained and speak the local language, to evaluate the Pal-Care intervention. We will conduct 20 key informant interviews/KIIs (or until saturation is reached), representing Pal-Care clinical team members, CHWs and patients/caregivers, who participated in the intervention at TMC, India. Clinicians will include social workers, oncology nurses, cancer center administrators, counselors, and palliative care oncologists. Patients/ caregivers will be purposefully selected to represent experiences across different cancers, clinical problems and assigned CHWs. Interviews will be performed in-person or over a telehealth platform, as needed. Interviews will query barriers, facilitators, optimal strategies, experiences, needs and expectations for palliative care delivery. Interviews will be digitally recorded, transcribed and analyzed.
This invention is composition comprising a highly purified, substantially endotoxin-free polysaccharide preparation suitable for use as a parenterally administered pharmaceutical, and the method for producing the composition. The process produces a substantially endotoxin-free polysaccharide composition using a size separation technique in which the low molecular weight impurities are removed first, with a subsequent separation of the endotoxin from the polysaccharide, again, by size separation. Suitable size separation techniques include gel fitration, or more preferably, ultrafiltration. In the preferred embodiment of the invention, the polysaccharide arabinogalactan is first ultrafiltered using a 10,000 dalton membrane; the low molecular weight impurities (<10,000 da) are discarded. The retentate is ultrafiltered using a 100,000 dalton membrane; the high molecular weight retentate, which contains the endotoxin, is discarded, leaving a substantially purified endotoxin free arabinogalactan composition in the filtrate. Other polysaccharides such as dextran, mannan, and gum arabic are also well suited for this purification technique. The process and products produced thereby are well suited for use in parenteral pharmacuetical compositions.
Plasma and urinary uric acid concentration, plasma phytochemical content and inflammatory biomarkers will be measured in order to elucidate the effects of an acute dose of tart cherry juice on indices related to the condition of gout.

Participants will be required to attend the laboratory at a range of time points over two periods of 96 hours, separated by a 7 day washout period, to provide blood samples. In order to provide a baseline sample, participants will attend the laboratory in the morning following an overnight fast and voiding of any urine. Following this participants will be given 30mls (30 mls provides 323 mg/380 µmol of anthocyanins) of tart cherry juice or placebo, diluted with 60 mls of water to consume within 10 minutes. Participants will be required to consume identical dosages of the supplement immediately prior to evening meals and breakfasts (or same time each morning following blood sampling if non-breakfast eater) over the next 96 hours. Further blood and urine samples will be collected at 1, 2, 3, 5, 8, 24, 26, 48, 50, 72, 74 and 96 hours and will require participants to return to the laboratory at each of these time points. Following the first period of supplementation participants will complete a 7 day washout period in which they will not be required to attend the laboratory. Following the washout period they will repeat the supplementation period consuming the supplement they did not receive during the first period.
Participants will receive roxadustat as an oral tablet, 3 times per week (TIW) for up to a maximum of 24 weeks. If a participant require roxadustat \<60 milligrams (mg)/week to maintain hemoglobin (Hb) levels, the dose frequency will be reduced in a stepwise manner, for example, to twice weekly (BIW), and then once weekly (QW). For participants converted from an ESA, the initial roxadustat dose will be based on the average prescribed ESA dose in the last 4 weeks (for epoetin alfa and darbepoetin alfa) or 8 weeks (for methoxy polyethylene glycol-epoetin beta \[Mircera®\]). For participants with \<6 weeks of prior ESA use, the initial roxadustat dose will be based on a 2-tiered, weight-based dosing scheme. Dose adjustment evaluations will be made every 4 weeks and doses will be titrated based on Hb level and rate of Hb change. The prescribed dose will not exceed the maximum allowable dose of 3.0 mg/kilogram (kg)/dose or 400 mg per dose, whichever is lower.
The usual sedatives used for endoscopy are meperidine (Demerol) and midazolam (Versed). Benadryl (Diphenhydramine) is often used in addition to these medications in an effort to improve sedation. There is little published information regarding the use of diphenhydramine in conscious sedation. It is recognized that certain patients have features that predict difficult sedation such as prescription sedative use or heavy alcohol use. In addition, prolonged procedures like ERCP and EUS require higher doses of sedatives. Diphenhydramine may improve the quality of sedation in patients undergoing endoscopic retrograde cholangio-pancreatography (ERCP) or endoscopic ultrasound (EUS) procedures. You are being asked to participate because you are already scheduled to undergo one of these procedures.
Perioperative atrial fibrillation (AF) and myocardial injury after noncardiac surgery (MINS) are among the most common serious complications occurring after thoracic surgery. AF is the most common perioperative cardiac arrhythmia. The incidence of perioperative AF in patients undergoing major thoracic surgery ranges from 10% in low-risk patients to as high as 20% in high-risk patients. The course of patients with perioperative AF is frequently complicated by hemodynamic instability, problems with managing anticoagulation in the early postoperative period, prolonged intensive care unit and hospital stays, and increased costs. Patients who develop perioperative AF (POAF) or MINS also have a significantly increased risk of death and stroke.

Colchicine is an inexpensive drug and a highly effective anti-inflammatory agent that holds great potential for preventing POAF and MINS in patients undergoing thoracic surgery. Data from cardiac surgery patients suggest that prevention of POAF using colchicine is feasible, but whether this concept is also applicable to patients undergoing thoracic surgery, where the risk of POAF is lower and underlying mechanisms may be different, is currently unclear. The 'Colchicine for the prevention of perioperative AF' (COP-AF) trial has been designed as a large randomized, double blind, placebo controlled trial to determine whether colchicine, a potent, safe and inexpensive anti-inflammatory drug, lowers the risk of perioperative AF, MINS, and other inflammatory complications in patients undergoing thoracic surgery. The primary objective of this trial is to determine whether a 10-day course of colchicine 0.5mg twice daily reduces the incidence of perioperative AF and MINS within 14 days after thoracic surgery.
BACKGROUND: Approximately 50% of children experience a cardiac murmur at some point in their lives; <1% of these murmurs are attributed to congenital heart disease (CHD). Cardiac murmur might be the first clinical sign of a significant CHD in children. Despite careful routine medical examinations at birth, approximately 50% of CHD cases could remain unrecognised.
OBJECTIVE: Cardiovascular symptoms and signs could be specific or non-specific in neonates and children with heart murmurs. Knowledge about red flags in history and physical examinations, and syndromic associations of common CHDs are important. Auscultatory skills to identify systolic, diastolic and continuous murmurs and heart sounds are essential. Differential diagnosis should be formulated based on the location of maximum intensity of murmurs. Younger infants and children with pathological murmurs and red-flag signs should be promptly referred to local paediatric cardiology services for further investigations.
DISCUSSION: Significant skill and knowledge are required for the identification of critical murmurs and associated cardiovascular problems. This review provides a simplified comprehensive update on cardiac murmurs and associated conditions in neonates and children.
Participants will receive TZP subcutaneously (SC) and MIBA for 24 weeks. Participants in Group A will be randomized (Randomization 2) to groups C and D at week 24.
The present invention provides a method of reducing a level of a toxic protein in the cytosol of a cell, the method generally involving contacting the cell with an agent that induces a survival response by the cell. The present invention provides a method of reducing a level of a toxic protein in a cell, the method generally involving contacting the cell with an agent that induces sequestration of the toxic protein in an inclusion body in the cell. The present invention further provides methods of identifying an agent that induces sequestration of a toxic protein into an inclusion body. The present invention further provides methods of increasing the yield of a recombinant protein synthesized by a genetically modified prokaryotic or eukaryotic host cell. The present invention provides methods for treating disorders associated with the presence in a cell of a toxic protein, the methods generally involving administering to a subject having such a disorder an agent that induces a survival response in a cell that has the toxic protein, e.g., an agent that induces sequestration of the toxic protein in an inclusion body in the cell. The present invention further provides agents that induce a survival response by a cell; agents that induce sequestration of a toxic protein in an inclusion body in a cell; and compositions that include such agents.
BACKGROUND/AIM: This study aimed to investigate the role of NOTCH receptor 1 (NOTCH1)-mediated activation of microglia in the L5-S2 spinal dorsal horn in chronic prostatitis pain.
MATERIALS AND METHODS: Rats were divided into chronic prostatitis (CP) group and control group. Complete Freund's adjuvant was injected into the prostate, and prostate pathology and pain-related behavior were monitored to assess the successful establishment of the CP-related pain model. The dorsal horn of the L5-S2 spinal cord was collected for the detection of ionized calcium-binding adapter molecule 1 (IBA-1) and NOTCH1 expression by quantitative real time polymerase chain reaction and the detection of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) by enzyme-linked immunosorbent assay. Electrical excitability was assessed with whole-cell patch clamp. In addition, NOTCH1 receptor inhibitor or inhibitor of microglial cell activation was injected into the subarachnoid space, and the pro-inflammatory cytokines in the spinal cord were detected.
RESULTS: In the CP group, the expression of NOTCH1, IBA-1, TNF-α and IL-1β began to increase at 4 days, peaked at 12 days, and began to decline at 24 days, and it was significantly higher than in the control group (p<0.01). Inhibition of microglia or NOTCH1 receptor markedly reduced the content of TNF-α and IL-1β in the spinal cord (p<0.05). At 4, 12 and 24 days, the amplitude and frequency of neuronal action potential increased and the threshold decreased markedly as compared to the control group (p<0.05), and spontaneous action potential was noted.
CONCLUSION: NOTCH1 mediates the activation of microglia in the L5-S2 spinal cord, leading to the secretion of inflammatory factors and enhanced electrical excitability of neurons, which is related to persistent and refractory chronic prostatitis-related pain.
This cross-sectional study examined the cognitive performance of crystallized intelligence (Gc) and fluid intelligence (Gf) in 340 individuals, comparing adults (aged 22-45) to adolescents (aged 16-21) in two groups of etiologies. Down syndrome (DS) and non-specific intellectual disability (NSID). The aim was to estimate whether their cognitive performance reflected accelerated, stable, or continuous trajectories. Participants were assessed using the Vocabulary, Similarities, Block Design, and Raven Matrix tests. ANOVA analysis indicated that adults exhibited higher scores than adolescents on three of the crystallized and fluid intelligence tests, with similar trends observed in the Raven Matrix test, thus supporting the Compensation Age Theory. Participants with NSID exhibited higher scores in Vocabulary than participants with DS. Participants with DS exhibited higher scores in Block Design and Raven than participants with NSID. There was no difference between the groups in Similarities, suggesting that the verbal ability of individuals with DS is not so impaired relative to participants with NSID. Graph analysis demonstrated divergent Gc-Gf networks between the two groups of etiologies. The DS etiology revealed more coherent connections between crystallized and fluid intelligence, especially in adulthood, compared to the diffuse and absent connections seen in adults with NSID. Thus, the relative strength in Similarities and the more coherent Gc-Gf interconnections in the DS etiology suggested a more coherent and not-so-impaired profile in a clear diagnostic etiology such as DS, especially in adulthood, compared to unclear genetic etiologies such as NSID. The findings hold educational implications for adults with ID with and without Down syndrome at least until their 40's as a time for growth and development, perhaps serving as a protective factor against possible cognitive decline in the future.
This invention comprises methods of modifying sexual behaviour in animals, and of use of these methods in pest control. The methods of the invention involve disrupting the function of a pheromone recognition area of the brain of an animal, specifically the vomeronasal organ (VNO). Compositions useful in the methods of the invention and are also provided. Compositions of the invention comprise antibody-cytotoxin and pheromone-cytotoxin conjugates. Useful cytotoxins include ricin A chain and domoic acid. Useful pheromones include those structurally related to dodecyl acetate including dodecyl acetate itself and (Z)-7-dodecen-1-yl acetate. Useful antibodies include monoclonal antibodies raised to the NMDAR1 sub-chain of the NMDA (N-methyl-D-aspartate) glutamate receptor which is present on the VNO.